Frontiers in Immunology (Sep 2021)

Evaluation of the Diagnostic Value of Non-criteria Antibodies for Antiphospholipid Syndrome Patients in a Chinese Cohort

  • Chaojun Hu,
  • Chaojun Hu,
  • Siting Li,
  • Siting Li,
  • Zhijuan Xie,
  • Zhijuan Xie,
  • Hanxiao You,
  • Hanxiao You,
  • Hui Jiang,
  • Hui Jiang,
  • Yu Shi,
  • Yu Shi,
  • Wanting Qi,
  • Wanting Qi,
  • Jiuliang Zhao,
  • Jiuliang Zhao,
  • Qian Wang,
  • Qian Wang,
  • Xinping Tian,
  • Xinping Tian,
  • Mengtao Li,
  • Mengtao Li,
  • Yan Zhao,
  • Yan Zhao,
  • Xiaofeng Zeng,
  • Xiaofeng Zeng

DOI
https://doi.org/10.3389/fimmu.2021.741369
Journal volume & issue
Vol. 12

Abstract

Read online

ObjectiveAlthough specific anti-phospholipid antibodies (aPLs) have been used in the diagnosis of the antiphospholipid syndrome (APS) for years, new biomarkers are required to increase its diagnostic and risk-predictive power. This study aimed to explore the value of several non-criteria aPLs in a Chinese cohort.MethodsA total of 312 subjects, namely, 100 patients diagnosed with primary APS, 51 with APS secondary to SLE, 71 with SLE, and 90 healthy controls, were recruited. Serum anticardiolipin (aCL) IgG/IgM/IgA, anti-β2-glycoprotein I (aβ2GPI) IgG/IgM/IgA, anti-phosphatidylserine/prothrombin antibodies (aPS/PT) IgG/IgM, and anti-annexin A5 antibodies (aAnxV) IgG/IgM were tested using ELISA kits.ResultsOf the total number of patients, 30.46% and 6.62% with APS were positive for aCL or aβ2GPI IgA, respectively, while 39.07% and 24.50% were positive for aAnxV or aPS/PT for at least one antibody (IgG or IgM). The addition test of aCL IgA and aAnxV IgM assists in identifying seronegative APS patients, and IgG aPS/PT was linked to stroke.ConclusionDetection of aCL IgA, aβ2GPI IgA, aAnxV IgG/M, and aPS/PT IgG/M as a biomarker provides additive value in APS diagnosis and would help in risk prediction for APS patients in medical practice.

Keywords